Literature DB >> 15358708

Penetration of newer quinolones in the empyema fluid.

I E Liapakis1, I Kottakis, M N Tzatzarakis, A M Tsatsakis, M S Pitiakoudis, P Ypsilantis, R W Light, C E Simopoulos, D E Bouros.   

Abstract

The degree of penetration of newer quinolones into the pleural fluid has not been studied. The objective of the present study was to determine the degree to which moxifloxacin and levofloxacin penetrate into empyemic pleural fluid using a new rabbit model of empyema. An empyema was created via the intrapleural injection of turpentine (1 mL), followed 24 h later by instillation of 2 mL (1 x 10(10)) Escherichia coli bacteria (ATCC 35218) into the pleural space of New Zealand white rabbits. After an empyema was verified by thoracentesis and pleural fluid analysis, moxifloxacin and levofloxacin (25 mg.kg(-1) for both, i.v.) were administered. Antibiotic levels were determined in samples of pleural fluid and in blood collected serially over 12 h. Antibiotic levels were measured using HPLC. Each of the antibiotics penetrated well into the empyemic pleural fluid. Antibiotic penetration was the greatest for moxifloxacin (area under the curve (AUC) for pleural fluid/blood (AUCPF/AUCblood) ratio=1.37) followed by levofloxacin (ratio=1.13). The time to equilibration between the pleural fluid and blood antibiotic levels was more rapid for moxifloxacin (3.9 h) than for levofloxacin (4.4 h). With moxifloxacin, the peak pleural fluid concentration (Cmax,PF) was 2.77 microg.mL(-1) and occurred at a time to maximum pleural fluid concentration (Tmax,PF) of 6 h after infusion and decreased thereafter. The peak blood concentration (Cmax,blood) was 4.81 microg.mL(-1) at 1 h after administration. With levofloxacin, the peak pleural fluid level (Cmax,PF=1.39 microg.mL(-1)) occurred at 6 h (Tmax,PF=6 h) after infusion. The Cmax,blood was 1.88 microg.mL(-1) at 1 h after administration. In conclusion, differences were found in the degree of penetration of the two quinolones into infected pleural fluid in rabbits. The clinical significance of these differences is unknown. More studies are needed to evaluate the pharmacokinetic parameters in the pleural space in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358708     DOI: 10.1183/09031936.04.00007804

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.

Authors:  Kalliopi Chatzika; Katerina Manika; Paschalina Kontou; Georgia Pitsiou; Despina Papakosta; Konstantinos Zarogoulidis; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

2.  Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.

Authors:  Maria Saroglou; Stavros Tryfon; Georgios Ismailos; Ioannis Liapakis; Manolis Tzatzarakis; Aristidis Tsatsakis; Apostolos Papalois; Demosthenes Bouros
Journal:  J Inflamm (Lond)       Date:  2010-05-18       Impact factor: 4.981

3.  Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement.

Authors:  Tatsuyoshi Ikeue; Hiroshi Yoshida; Eiichiro Tanaka; Issei Ohi; Susumu Noguchi; Akari Fukao; Satoshi Terashita; Sadao Horikawa; Takakazu Sugita
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

Review 4.  Management of Pleural Infection.

Authors:  Anand Sundaralingam; Radhika Banka; Najib M Rahman
Journal:  Pulm Ther       Date:  2020-12-09

5.  Antimicrobial resistance development following surgical site infections.

Authors:  Daniela Călina; Anca Oana Docea; Lucica Rosu; Ovidiu Zlatian; Alexandra Floriana Rosu; Florin Anghelina; Otilia Rogoveanu; Andreea Letiția Arsene; Alina Crenguța Nicolae; Cristina Manuela Drăgoi; John Tsiaoussis; Aristides M Tsatsakis; Demetrios A Spandidos; Nikolaos Drakoulis; Eliza Gofita
Journal:  Mol Med Rep       Date:  2016-12-13       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.